Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lidia Rajzer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Przeglad Lekarski|August 20, 2009
[The role of cytokines released by keratinocytes in psoriasis pathogenesis]Lidia Rajzer, Anna Wojas-Pelc
Przeglad Lekarski|March 14, 2003
[Psoriasis and cardio-vascular disorders]Anna Wojas-Pelc, Lidia Rajzer, Marek Rajzer
Przeglad Lekarski|April 20, 2007
[The latest diagnostical methods and therapy in melanoma]Anna Wojas-Pelc, Lidia Rajzer, Andrzej Jaworek, et al.
The Journal of Dermatological Treatment|December 10, 2024
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52Steven R Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Journal of the American Academy of Dermatology|April 30, 2024
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasisSteven R Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Przeglad Lekarski|August 20, 2009
[The role of cytokines released by keratinocytes in psoriasis pathogenesis]Lidia Rajzer, Anna Wojas-Pelc
Przeglad Lekarski|March 14, 2003
[Psoriasis and cardio-vascular disorders]Anna Wojas-Pelc, Lidia Rajzer, Marek Rajzer
Przeglad Lekarski|April 20, 2007
[The latest diagnostical methods and therapy in melanoma]Anna Wojas-Pelc, Lidia Rajzer, Andrzej Jaworek, et al.
The Journal of Dermatological Treatment|December 10, 2024
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52Steven R Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Journal of the American Academy of Dermatology|April 30, 2024
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasisSteven R Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Pageof 1